Repare Therapeutics Inc. reported data highlighting the clinical benefits of camonsertib, an oral small molecule ATR inhibitor, combined with palliative radiation. These findings were presented at the American Society for Radiation Oncology (ASTRO) annual meeting.
The data, from a clinical trial conducted in collaboration with Memorial-Sloan Kettering Cancer Center, showed that the combination has the potential to radiosensitize for higher clinical benefit. This was observed in patients with metastatic tumors harboring pathogenic ATM mutations.
The early Phase 1 data provided an encouraging look at the response rate and safety profile of this combination. This supports the broad clinical potential of camonsertib in genotypically-selected cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.